Tezepelumab improved chronic rhinosinusitis with nasal polyps in a Patient with aspirin exacerbated respiratory disease

• Published in: Respiratory medicine case reports Vol. 50; p. 102041
• Main Authors: Yamashita, Yuga, Terada, Kosuke, Kodama, Yuka, Nakadegawa, Ryo, Masumitsu, Hinako, Motobayashi, Yuto, Osada, Reeko, Takayasu, Hirokazu, Masumoto, Nami, Kaneko, Takeshi, Tsurikisawa, Naomi
• Format: Report
• Language: English
• Published: 01.01.2024
• ISSN: 2213-0071; 2213-0071
• DOI: 10.1016/j.rmcr.2024.102041

IntroductionPatients with chronic rhinosinusitis with nasal polyps (CRSwNP) and aspirin-exacerbated respiratory disease (AERD) have more severe sinus disease than those without AERD. CRSwNP associated with type 2 inflammation and AERD can be difficult to control with standard medical therapy and sinus surgery.Case study74-year-old Japanese woman with chronic sinusitis since age 50 and asthma since age 60. At age 64, she began to experience asthma exacerbations and was started on short-term corticosteroid therapy with prednisolone. At age 70, she experienced urticaria, nasal congestion, and wheezing after taking an NSAID; based on an NSAID provocation test, we diagnosed the patient with AERD and CRSwNP. A diagnosis of severe eosinophilic chronic rhinosinusitis was also made based on the scoring system and algorithm used in the Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis.ResultsTreatment with benralizumab (30 mg), formoterol-fluticasone combination via pressurized metered inhaler (1000 μg), and leukotriene receptor antagonist improved the asthma symptoms and exacerbations so the short-term prednisolone was stopped; however, nasal congestion and olfactory dysfunction (hyposmia) persisted, and peripheral blood eosinophil count (peak, 1500 cells/μL) and fractional exhaled nitric oxide (peak, 42 ppb) became elevated. Swapping the benralizumab for monthly tezepelumab (210 mg) improved not only the asthma symptoms but also the nasal congestion, olfactory dysfunction, eosinophil count (<300 cells/μL), and fractional exhaled nitric oxide level [8ppb].ConclusionChanging from benralizumab to tezepelumab improved asthma symptoms, nasal obstruction, and olfactory dysfunction in elderly, female, Japanese patient with AERD and CRSwNP.